フローサイトメーター

世界のリサーチ分野のお客さまへ先端の検査装置のご案内です。

  • 神戸:078-992-6272
  • 東京:03-5434-8556

【受付時間09:00~17:35※土日休日を除く/その他休日はサイト上で告知

お問い合わせ

sysmex

フローサイトメーターsysmex

CyFlow CD14 Low Endotoxin

品番 BD085182
抗体名 Anti-Hu CD14 LOW END,MEM-18
包装単位 0.1 mg
濃度 1 mg/ml
容量 0.1 ml
関連製品
(アイソタイプコントロール)
Mouse IgG1 Low Endotoxin (AK478344)
反応性|交差吸着 Human | Non-Human Primates レーザー
抗原 CD14, LPS-R 最大蛍光波長 -
クローン MEM-18 最大励起波長 -
ホスト Mouse 標識/Format Low Endotoxin
アイソタイプ IgG1 研究分野 Immunophenotyping
クローナリティ monoclonal 用途

Flow cytometry
Immunoprecipitation
Western blot
Functional assays
ELISA

Anti-Hu CD14 LOW END,MEM-18

特異性

The mouse monoclonal antibody MEM-18 recognizes CD14 antigen, a 53-55 kDa GPI (glycosylphosphatidylinositol)-linked membrane glycoprotein expressed on monocytes, macrophages and weakly on granulocytes; also expressed by most tissue macrophages. In human, the epitope recognized by MEM-18 is located between amino acids 57-64.

抗原情報

CD14 is a 55 kDa GPI-anchored glycoprotein, constitutively expressed on the surface of mature monocytes, macrophages, and neutrophils, where serves as a multifunctional lipopolysaccharide receptor; it is also released to the serum both as a secreted and enzymatically cleaved GPI-anchored form. CD14 binds lipopolysaccharide molecule in a reaction catalyzed by lipopolysaccharide-binding protein (LBP), an acute phase serum protein. The soluble sCD14 is able to discriminate slight structural differences between lipopolysaccharides and is important for neutralization of serum allochthonous lipopolysaccharides by reconstituted lipoprotein particles. CD14 affects allergic, inflammatory and infectious processes.

利用方法

保存方法

Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.

安定性情報

Do not use after expiration date stamped on vial label.

レファレンス

• Angel CE, Lala A, Chen CJ, Edgar SG, Ostrovsky LL, Dunbar PR: CD14+ antigen‑presenting cells in human dermis are less mature than their CD1a+ counterparts. Int·Immunol. 2007·Nov; 19(11):1271‑9. <·PMID:·17804688·>
• Asai Y, Makimura Y, Kawabata A, Ogawa T: Soluble CD14 discriminates slight structural differences between lipid as that lead to distinct host cell activation. J·Immunol. 2007·Dec·1; 179(11):7674‑83. <·PMID:·18025213·>
• Bazil V, Baudys M, Hilgert I, Stefanova I, Low MG, Zbrozek J, Horejsi V: Structural relationship between the soluble and membrane‑bound forms of human monocyte surface glycoprotein CD14. Mol·Immunol. 1989·Jul; 26(7):657‑62. <·PMID:·2779588·>
• Bazil V, Horejsi V, Baudys M, Kristofova H, Strominger JL, Kostka W, Hilgert I: Biochemical characterization of a soluble form of the 53‑kDa monocyte surface antigen. Eur·J·Immunol. 1986·Dec; 16(12):1583‑9. <·PMID:·3493149·>
• Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·>
• Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single‑molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int·Immunol. 2007·May; 19(5):675‑84. <·PMID:·17446208·>
• Fernández-Real JM, Broch M, Richart C, Vendrell J, López-Bermejo A, Ricart W: CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J·Clin·Endocrinol·Metab. 2003·Apr; 88(4):1780‑4. <·PMID:·12679473·>
• Funda DP, Tucková L, Farré MA, Iwase T, Moro I, Tlaskalová-Hogenová H: CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect·Immun. 2001·Jun; 69(6):3772‑81. <·PMID:·11349042·>
• Iwaki D, Nishitani C, Mitsuzawa H, Hyakushima N, Sano H, Kuroki Y: The CD14 region spanning amino acids 57‑64 is critical for interaction with the extracellular Toll‑like receptor 2 domain. Biochem·Biophys·Res·Commun. 2005·Mar·4; 328(1):173‑6. <·PMID:·15670766·>
• Juan TS, Hailman E, Kelley MJ, Wright SD, Lichenstein HS: Identification of a domain in soluble CD14 essential for lipopolysaccharide (LPS) signaling but not LPS binding. J·Biol·Chem. 1995·Jul·21; 270(29):17237‑42. <·PMID:·7542233·>
• Lodrup Carlsen KC, Granum B: Soluble CD14: role in atopic disease and recurrent infections, including otitis media. Curr·Allergy·Asthma·Rep. 2007·Nov; 7(6):436‑43. <·PMID:·17986374·>
• Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J: Yersinia V‑antigen exploits toll‑like receptor 2 and CD14 for interleukin 10‑mediated immunosuppression. J·Exp·Med. 2002·Oct·21; 196(8):1017‑24. <·PMID:·12391013·>
• Stöckl J, Majdic O, Fischer G, Maurer D, Knapp W: Monomorphic molecules function as additional recognition structures on haptenated target cells for HLA‑A1‑restricted, hapten‑specific CTL. J·Immunol. 2001·Sep·1; 167(5):2724‑33. <·PMID:·11509616·>
• Weiss TS, Lichtenauer M, Kirchner S, Stock P, Aurich H, Christ B, Brockhoff G, Kunz-Schughart LA, Jauch KW, Schlitt HJ, Thasler WE: Hepatic progenitor cells from adult human livers for cell transplantation. Gut. 2008·Aug; 57(8):1129‑38. <·PMID:·18417531·>
• McMichael AJ, Beverley PCL, Cobbold S, et al (Eds): Leucocyte Typing III, White Cell Differentiation Antigens. Oxford·University·Press,·Oxford. 1987; 1‑1050. <·NLM·ID:·8913266·>
• Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·>
• Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·>

Available Safety Data Sheets

CyFlow™ monoclonal antibodies SDS CA EN

Available Technical Data Sheets

CyFlow™ CD14 Low Endotoxin (MEM-18) BD085182 TDS (US)